Array comparative genomic hybridization analysis of chromosomal imbalances and their target genes in gastrointestinal stromal tumors

被引:60
作者
Assamaki, Reetta
Sarlomo-Rilkala, Marit
Lopez-Guerrero, Jose Antonio
Lasota, Jerzy
Andersson, Leif C.
Llombart-Bosch, Antonio
Miettinen, Markku
Knuutila, Sakari
机构
[1] Univ Helsinki, Dept Pathol, Haartman Inst, FI-00014 Helsinki, Finland
[2] Univ Helsinki, HUSLAB, FI-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Helsinki, Finland
[4] Fdn Inst Valenciano Oncol, Mol Biol Unit, Valencia, Spain
[5] Armed Forces Inst Pathol, Dept Soft Tissue Pathol, Washington, DC 20306 USA
[6] Univ Valencia, Dept Pathol, E-46003 Valencia, Spain
关键词
D O I
10.1002/gcc.20439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The tumors characteristically harbor KIT or PDGFRA mutations, and mutant tumors respond to imatinib mesylate (Glivec (TM)). Chromosomal imbalances resulting in altered gene dosage are known to have a role in the molecular pathogenesis of these tumors, but the target genes remain to be identified. The present study aimed to identify some of these genes. In total, 35 GIST samples were screened for chromosomal imbalances by array-based comparative genomic hybridization. A cDNA array was used to define the minimal common overlapping areas of DNA copy number change. Eight confirmative, replicate hybridizations were performed using an oligonucleotide array. The most recurrent copy number losses were localized to 14q, 22q, and 1p. Gains were less common with 8q being the most recurrent. Two recurrent deleted regions of 14q were 14q11.2 harboring the PARP2, APEX1, and NDRG2 genes and 14q32.33 harboring SIVA. Additional target candidates were NF2 at chromosome 22, CDKN2A/2B at 9p, and ENO1 at 1p for copy number losses, and MYC at 8q for copy number gains. Array CGH proved to be an effective tool for the identification of chromosome regions involved in the development and progression of GISTs. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:564 / 576
页数:13
相关论文
共 47 条
[1]   Cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss in a case of Pseudo-Meigs' syndrome [J].
Amant, F ;
Debiec-Rychter, M ;
Schoenmakers, EFPM ;
Hagemeijer-Hausman, A ;
Vergote, I .
GENES CHROMOSOMES & CANCER, 2001, 32 (04) :324-329
[2]   Gene amplifications in osteosarcoma -: CGH microarray analysis [J].
Atiye, J ;
Wolf, M ;
Kaur, S ;
Monni, O ;
Böhling, T ;
Kivioja, A ;
Tas, É ;
Serra, M ;
Tarkkanen, M ;
Knuutila, S .
GENES CHROMOSOMES & CANCER, 2005, 42 (02) :158-163
[3]   Progenetix.net: an online repository for molecular cytogenetic aberration data [J].
Baudis, M ;
Cleary, ML .
BIOINFORMATICS, 2001, 17 (12) :1228-1229
[4]   Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors) [J].
Breiner, JA ;
Meis-Kindblom, J ;
Kindblom, LG ;
McComb, E ;
Lin, J ;
Nelson, M ;
Bridge, JA .
CANCER GENETICS AND CYTOGENETICS, 2000, 120 (02) :111-116
[5]   Biological significance of chromosomal imbalance aberrations in gastrointestinal stromal tumors [J].
Chen, Y ;
Tzeng, CC ;
Liou, CP ;
Chang, MY ;
Li, CF ;
Lin, CN .
JOURNAL OF BIOMEDICAL SCIENCE, 2004, 11 (01) :65-71
[6]   Allelic loss of 14q32 in the pathogenesis of gastrointestinal and ampullary malignancies: mapping of the target region to a 17 cM interval [J].
Dai, YC ;
Ho, CL ;
Tsai, YC ;
Hsu, YH ;
Chang, YC ;
Liu, HS ;
Chen, HHW ;
Chow, NH .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2005, 131 (02) :94-100
[7]   Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants [J].
Debiec-Rychter, M ;
Cools, J ;
Dumez, H ;
Sciot, R ;
Stul, M ;
Mentens, N ;
Vranckx, H ;
Wasag, B ;
Prenen, H ;
Roesel, J ;
Hagemeijer, A ;
Van Oosterom, A ;
Marynen, P .
GASTROENTEROLOGY, 2005, 128 (02) :270-279
[8]   Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation [J].
Debiec-Rychter, M ;
Lasota, J ;
Sarlomo-Rikala, M ;
Kordek, R ;
Miettinen, M .
CANCER GENETICS AND CYTOGENETICS, 2001, 128 (01) :24-30
[9]   N-myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation [J].
Deng, YC ;
Yao, LB ;
Chau, L ;
Ng, SSM ;
Peng, Y ;
Liu, XP ;
Au, WS ;
Wang, JC ;
Li, FY ;
Ji, SP ;
Han, H ;
Nie, XY ;
Li, Q ;
Kung, HF ;
Leung, SY ;
Lin, MCM .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (03) :342-347
[10]  
El-Rifai W, 2000, CANCER RES, V60, P3899